Pediococcus acidilactici JYPA-30 for improving female mastitis

Mastitis is a common disease in women, which can be divided into acute suppurative mastitis, periareolar fistula, plasma cell mastitis, etc. according to the different causes. The most common is acute suppurative mastitis. The incidence rate of acute mastitis in primipara is as high as 2%~4%, which is twice as much as that in multipara. After the onset of the disease, not only is the mother experiencing abnormal pain, but she is also unable to continue breastfeeding, which affects the health of the baby.

Traditional methods for treating mastitis often use antibiotics for anti-inflammatory treatment. The most commonly used antibiotics are penicillin, erythromycin, cephalosporins, etc. Although antibiotics have fast efficacy and obvious effects, they treat the symptoms rather than the root cause, leading to recurrent symptoms. Moreover, the use of antibiotics will inevitably have a certain impact on feeding. Therefore, many patients choose traditional Chinese medicine treatment for mastitis, which is safe and thorough. However, the traditional Chinese medicine composition used to treat mastitis is complex and prone to mismatched prescriptions; Moreover, traditional Chinese medicine treatment has a longer course of treatment and slower effectiveness, making it unsuitable for lactating patients with mastitis.

In response to the problem of recurrent symptoms caused by antibiotic treatment and long and slow efficacy of traditional Chinese medicine treatment in existing methods for treating mastitis, the present invention provides Pediococcus acidilactici JYPA-30 and its bacterial agent and application for improving female mastitis.

As of now, Zhongke -Jiayi has obtained a total of 28 invention patents and 2 international invention patents. Zhongke- Jiayi team has made outstanding contributions in the field of disciplines through dedicated research and continuous innovation, and has gained high recognition from the industry and customers. Zhongke- Jiayi will continue to increase research and development investment, accelerate the pace of innovation, further enhance technological innovation capabilities, and promote the scientific and technological development of China's probiotics industry.